Zobrazeno 1 - 10
of 799
pro vyhledávání: ''
Autor:
Nancy L. Bartlett, Felicia Gomez, Matthew Mosior, Malachi Griffith, Anne Fischer, Michelle Becker-Hapak, Mark P. Foster, Melissa M. Berrien-Elliott, Alina D. Schmidt, Marcus Watkins, Amanda F. Cashen, Kilannin Krysiak, Kami J. Maddocks, Nina D. Wagner-Johnston, Jingqin Luo, Obi L. Griffith, Zachary L. Skidmore, Todd A. Fehniger, Sweta Desai, Jeffrey P. Ward
Publikováno v:
Blood
New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for stem cell transplant and chimeric antigen receptor therapy. The CD30-targeted, antibody-drug
Autor:
Julio C. Chavez, James Drew, John P. Leonard, Erin Mulvey, Sonali M. Smith, Leandro Cerchietti, Nancy L. Bartlett, John L. Reagan, Jeffrey A. Jones, Ann S. LaCasce, Peter Martin, Maria Victoria Revuelta, Chengqing Wu
Publikováno v:
Blood. 139:1147-1159
Resistance to standard immunochemotherapy remains an unmet challenge in diffuse large B-cell lymphoma (DLBCL), and aberrant DNA methylation may contribute to chemoresistance. Promising early-phase results were reported with rituximab, cyclophosphamid
Autor:
R. Spencer Tong, Robert B. Gerbing, Todd A. Alonzo, Jeffrey W. Taub, Jim Wang, Lisa Eidenschink Brodersen, Reuven J. Schore, Maureen M. O'Brien, Amy Heerema-McKenney, Jason N. Berman, Shelton A Viola, Michael R. Loken, E. Anders Kolb, Betsy A. Hirsch, Alan S. Gamis, Karen M. Chisholm, Susana C. Raimondi, Nobuko Hijiya, Amy Beckman, Johann Hitzler, Todd E. Druley
Publikováno v:
Blood. 138:2337-2346
Myeloid leukemia in children with Down syndrome (ML-DS) is associated with young age and somatic GATA1 mutations. Because of high event-free survival (EFS) and hypersensitivity of the leukemic blasts to chemotherapy, the prior Children’s Oncology G
Autor:
Gandhi Damaj, Steven Le Gouill, Christophe Bonnet, Hervé Ghesquières, David Sibon, Marc André, Emmanuel Itti, Loïc Chartier, Françoise Kraeber-Bodéré, Luc Fornecker, Hervé Tilly, Vincent Ribrag, Franck Morschhauser, Jean-Philippe Jais, Caroline Bodet-Milin, Alina Berriolo-Riedinger, Krimo Bouhabdallah, Philippe Ruminy, Guillaume Cartron, Catherine Thieblemont, Remy Gressin, Reda Bouhabdallah, Corinne Haioun, Lucie Oberic, Thierry Jo Molina, René-Olivier Casasnovas, Pierre Feugier, Josette Brière, Thierry Lamy, Hervé Maisonneuve
Publikováno v:
Blood. 137:2307-2320
Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted Intern
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Anneke C.J. Ammerlaan, Ying Chen, Franco Locatelli, Christian M. Zwaan, Cristina Díaz-de-Heredia, Benoit Brethon, Christiane Chen-Santel, Ingrid Øra, Monique L. den Boer, Barbara Sleight, Bella Bielorai, Andrea Malone, Claudia Rossig, Marta Lopez-Yurda, Vincent H.J. van der Velden, Adriana Thano, Erica Brivio, Lucie Sramkova, Luciana Vinti, Inge M. van der Sluis, Karsten Nysom
Publikováno v:
Blood, 137(12), 1582-1590. American Society of Hematology
Blood
Blood
This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patie
Autor:
Asad Bashey, Carolyn Mulroney, Roy F. Chemaly, Paul Castillo, Ephraim J. Fuchs, Christopher G. Kanakry, Hillard M. Lazarus, Hongtao Liu, Per Ljungman, Jeffery J. Auletta, Stefan O. Ciurea, Jennifer A. Kanakry, Miguel-Angel Perales, Muhammad Bilal Abid, Randy Taplitz, Rizwan Romee, Richard Masiarz, Soyoung Kim, Amer Beitinjaneh, Marcie L. Riches, Christopher E. Dandoy, Taiga Nishihori, Min Chen, Krishna V. Komanduri, Kristin Page, Sunita Nathan, Miguel Angel Diaz, Maxwell M. Krem, Scott R. Goldsmith, Siddhartha Ganguly
Publikováno v:
Blood
Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft source and posttransplant cyclophosphamide (PTCy) in CMV infection is unc
Autor:
Richard J. Jones, Andrew R. Rezvani, Lawrence E. Morris, Peter Dawson, Joseph P. McGuirk, Eric S. Leifer, John M. Magenau, Paul O'Donnell, Chatchada Karanes, Steven M. Devine, Ephraim J. Fuchs, Mary M. Horowitz, Mary Eapen, Joseph H. Antin, Claudio G. Brunstein, Mitchell E. Horwitz, Brent R. Logan
Publikováno v:
Blood. 137:420-428
Results of two parallel phase II trials of transplantation of unrelated umbilical cord blood or bone marrow from HLA-haploidentical relatives provided equipoise for direct comparison of these donor sources. Between June 2012 and June 2018, 368 patien
Autor:
Bianca Rocca, Francesca Palandri, Giovanna Petrucci, Chiara Paoli, Cristina Bucelli, Benedetta Porro, Nicola Vianelli, Francesco Rodeghiero, Elena Rossi, Alessandra Iurlo, Carlo Patrono, Irene Bertozzi, Alessandro M. Vannucchi, Maria Luigia Randi, Andrea Timillero, Monica Carpenedo, Mauro Di Ianni, Giuseppe Carli, Alfredo Dragani, Silvia Betti, Denise Soldati, Elena Maria Elli, Eloise Beggiato, Valerio De Stefano, Daniele Cattaneo, Giuseppe Lanzarone, Alberto Tosetto, Viviana Cavalca, Marco Ruggeri, Giorgina Specchia, Alessandra Ricco, Paola Ranalli
Publikováno v:
Blood. 136:171-182
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet
Autor:
J. Mark Sloan, Shayna Sarosiek, Anthony C Shelton, Ramon Cruz, Amanda Schulman, Mary Ellen Migre, Vaishali Sanchorawala, Dina Brauneis, Meredith Mistark
Publikováno v:
Blood
Daratumumab, a monoclonal CD38 antibody, is approved in the treatment of myeloma, but its efficacy and safety in light-chain (AL) amyloidosis has not been formally studied. This prospective phase 2 trial of daratumumab monotherapy for the treatment o